Bayer, Novartis Near Settlement Over MS Drug

Law360, New York (January 12, 2007, 12:00 AM EST) -- Pharmaceutical companies Novartis AG and Bayer AG may soon be settling their differences over the production and marketing of multiple sclerosis drug Betaseron.

The companies jointly asked a court in California to postpone a deadline from Jan. 16 to Feb. 20 so they could continue settlement talks, the Financial Times Deutschland reported.

Currently, Bayer unit Schering and Novartis unit Chiron have a licensing deal over Betaseron set to end in 2008. Chiron exclusively produces the drug in the United States for Schering and receives a 22.5%...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.